Skip to content

OWC Pharmaceutical Research Corp.: 10-K/A filed 2013-04-16

What OWC Pharmaceutical Research Corp. reported in its annual report amendment filed 2013-04-16 (fiscal FY 2012): 12 published measures, 32 facts as tagged in accession 0001295345-13-000053.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2013-04-16
Fiscal period
fiscal FY 2012
Accession
0001295345-13-000053 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OWC Pharmaceutical Research Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-12-318,101USD
At 2011-12-317,927USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-87,413USD366
2008-03-07 to 2012-12-31-504,895USD1761
2011-01-01 to 2011-12-31-78,496USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-41,629USD366
2008-03-07 to 2012-12-31-429,968USD1761
2011-01-01 to 2011-12-31-67,457USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2012-01-01 to 2012-12-310USD366
2008-03-07 to 2012-12-310USD1761
2011-01-01 to 2011-12-310USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-12-3141,803USD366
2008-03-07 to 2012-12-31438,069USD1761
2011-01-01 to 2011-12-3175,380USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-12-318,101USD
At 2011-12-317,927USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-7,648USD366
2008-03-07 to 2012-12-31-9,456USD1761
2011-01-01 to 2011-12-31-1,808USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-12-3188,364USD
At 2011-12-3130,525USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2012-01-01 to 2012-12-3141,350USD366
2008-03-07 to 2012-12-31394,955USD1761
2011-01-01 to 2011-12-3164,633USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-01-01 to 2012-12-310USD366
2008-03-07 to 2012-12-3145,000USD1761
2011-01-01 to 2011-12-310USD365

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-12-31424,474USD
At 2011-12-31393,476USD

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-12-3112,003USD366
2008-03-07 to 2012-12-31339,833USD1761
2011-01-01 to 2011-12-3135,380USD365

Inspect the source

Entity
OWC Pharmaceutical Research Corp. / CIK 0001431934
Captured
SEC response SHA-256
5a62036473d89e622be102a608ba10aaa02db1a8778e5f34f9de1894da63b491

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001431934.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))